711 related articles for article (PubMed ID: 23356886)
1. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study.
Phiphatpatthamaamphan K; Vilaichone RK; Siramolpiwat S; Tangaroonsanti A; Chonprasertsuk S; Bhanthumkomol P; Pornthisarn B; Mahachai V
Asian Pac J Cancer Prev; 2016; 17(4):1903-7. PubMed ID: 27221874
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.
Lee JY; Kim N; Kim MS; Choi YJ; Lee JW; Yoon H; Shin CM; Park YS; Lee DH; Jung HC
Dig Dis Sci; 2014 Jun; 59(6):1235-43. PubMed ID: 24599773
[TBL] [Abstract][Full Text] [Related]
5. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
[TBL] [Abstract][Full Text] [Related]
6. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Auesomwang C; Maneerattanaporn M; Chey WD; Kiratisin P; Leelakusolwong S; Tanwandee T
J Gastroenterol Hepatol; 2018 Nov; 33(11):1822-1828. PubMed ID: 29804294
[TBL] [Abstract][Full Text] [Related]
7. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
[TBL] [Abstract][Full Text] [Related]
8. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
9. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Prapitpaiboon H; Mahachai V; Vilaichone RK
Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
[TBL] [Abstract][Full Text] [Related]
10. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
[TBL] [Abstract][Full Text] [Related]
11. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
13. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
[TBL] [Abstract][Full Text] [Related]
15. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
16. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Isomoto H; Inoue K; Furusu H; Nishiyama H; Shikuwa S; Omagari K; Mizuta Y; Murase K; Murata I; Kohno S
Helicobacter; 2003 Apr; 8(2):111-9. PubMed ID: 12662378
[TBL] [Abstract][Full Text] [Related]
17. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
19. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]